Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 7, 2011, Pages 1292-1300

  Myerson, J ^a   He, L ^a   Lanza, G ^a   Tollefsen, D ^a   Wickline, S A ^a  

^a WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

Imaging; Inhibitors; Nanotechnology; Pharmacology; Thrombin; Thrombosis

Indexed keywords

CHROMOGENIC SUBSTRATE; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; FLUOROCARBON; HEPARIN; THROMBIN; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ARTICLE; CAROTID ARTERY THROMBOSIS; CHEMICAL STRUCTURE; COMMON CAROTID ARTERY; CONTROLLED STUDY; COVALENT BOND; DRUG EFFICACY; DRUG MEGADOSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOSIS;

ACUTE DISEASE; AMINO ACID CHLOROMETHYL KETONES; ANIMALS; BINDING SITES; FLUOROCARBONS; MAGNETIC RESONANCE IMAGING; MICE; NANOPARTICLES; PARTIAL THROMBOPLASTIN TIME; SERINE PROTEINASE INHIBITORS; THROMBIN; THROMBOSIS;

EID: 79959858154     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04339.x     Document Type: Article

References (36)

1. Davies MJ. Anatomic features in victims of sudden coronary death. Coronary artery pathology. Circulation 1992; 85: i19-24.
2. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med Overseas Ed 2008; 359: 938-49.
3. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists. Chest 2004; 126: 204S-33S.
4. Schwartz RS, Burke A, Farb A, Kaye D, Lesser JR, Henry TD, Virmani R. Microemboli and microvascular obstruction in acute coronary thrombosis and sudden coronary death: relation to epicardial plaque histopathology. J Am Coll Cardiol 2009; 54: 2167-73.
5. Lee LV. Anticoagulants in coronary artery disease. Clin Cardiol 2008; 26: 615-28.
6. Turpie AG. The top four advances in antithrombotic care in the last year. Thromb Res 2008; 123: S2-6.
7. Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Int J Angiol 2008; 27: 176-92.
8. Bousser MG. Antithrombotic agents in the prevention of ischemic stroke. Cerebrovasc Dis 2009; 27: 12-9.
9. Gross P, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther 2009; 86: 139-46.
10. Kaiser B, Hauptmann J. Pharmacology of Synthetic Thrombin inhibitors of the tripeptide type. Cardiovasc Drug Rev 1992; 10: 71-87.
11. Srivastava S, Goswami LN, Dikshit DK. Progress in the design of low molecular weight thrombin inhibitors. Med Res Rev 2005; 25: 66-92.
12. Di Cera E. Thrombin. Mol Aspects Med 2008; 29: 203-54.
13. Wickline SA, Mason RP, Caruthers SD, Chen J, Winter PM, Hughes MS, Lanza GM. Fluorocarbon agents for multimodal molecular imaging and targeted therapeutics. In: Weissleder R, Ross BD, Rehemtulla A, Gambhir SS, eds. Molecular Imaging: Principles and Practice. Shelton, CT: Peoples Medical Publishing House, 2010: 542-73.
14. Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging 2007; 25: 667-80.
15. Peters D, Kastantin M, Kotamraju VR, Karmali PP, Gujraty K, Tirrell M, Ruoslahti E. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Nat Acad Sci 2009; 106: 9815-9.
16. Flaim SF. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Cells Blood Substit Immobil Biotechnol 1994; 22: 1043-54.
17. Winter PM, Caruthers SD, Wickline SA, Lanza GM. Molecular imaging by MRI. Curr Cardiol Rep 2006; 8: 65-9.
18. Bode W, Turk D, Karshikov A. The refined 1.9-Å crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1992; 1: 426-71.
19. Ivey ME, Little PJ. Thrombin regulates vascular smooth muscle cell proteoglycan synthesis via PAR-1 and multiple downstream signaling pathways. Thromb Res 2008; 123: 288-97.
20. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27: 27-36.
21. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature 2000; 407: 258-64.
22. Bretschneider E, Kaufmann R, Braun M, Nowak G, Glusa E, Schrör K. Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells. Br J Pharmacol 2001; 132: 1441-6.
23. Bretschneider E, Spanbroek R, Lötzer K, Habenicht AJ, Schrör K. Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cells. J Thromb Haemost 2003; 90: 704-9.
24. Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost 2006; 32 (Suppl. 1): 3-15.
25. Ghigliotti G, Waissbluth AR, Speidel C, Abendschein DR, Eisenberg PR. Prolonged activation of prothrombin on the vascular wall after arterial injury. Arterioscler Thromb Vasc Biol 1998; 18: 250-7.
26. Duguid JB. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol Bacteriol 1946; 58: 207-12.
27. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001; 104: 1280-5.
28. Vicente CP, He L, Pavão MSG, Tollefsen DM. Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice. Blood 2004; 104: 3965-70.
29. 2Cl-A selective affinity label for thrombin. Thromb Res 1979; 14: 969-73.
30. Westrick RJ, Winn ME, Eitzman DT. Murine models of vascular thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 2079-93.
31. 111In nanoparticles. Int J Cancer 2007; 120: 1951-7.
32. Lanza GM, Abendschein DR, Hall CS, Marsh JN, Scott MJ, Scherrer DE, Wickline SA. Molecular Imaging of Stretch-Induced Tissue Factor Expression in Carotid Arteries with Intravascular Ultrasound. Invest Radiol 2000; 35: 227-34.
33. 3 targeted Nanoparticle and 1.5 Tesla Magnetic Resonance Imaging. Cancer Res 2003; 63: 5838-43.
34. 3 Integrin-Targeted Nanoparticles. Circulation 2003; 108: 2270-4.
35. Collen D, Matsuo O, Stassen JM, Kettner C, Shaw E. In vivo studies of a synthetic inhibitor of thrombin. J Lab Clin Med 1982; 99: 76-83.
36. Kukreja N, Onuma Y, Daemen J, Serruys PW. The future of drug-eluting stents. Pharmacol Res 2008; 57: 171-80.